Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827911 | 0.87 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP1A2HTR2A | |
| SCHEMBL5840813 | 0.82 | PDE4A (0.38) | ALDH1A1LMNAFFAR4CYP3A4HPGD | |
| SCHEMBL17385939 | 0.82 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL701066 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNAFFAR4CYP3A4HPGD | |
| SCHEMBL9377735 | 0.80 | CYP1A2 (0.44) | ALDH1A1CYP3A4CYP1A2HTR2A | |
| SCHEMBL9513058 | 0.80 | CYP1A2 (0.41) | ALDH1A1FFAR4CYP3A4HPGDCYP1A2 | |
| SCHEMBL2292752 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL203680 | 0.78 | ALDH1A1 (0.43) | ALDH1A1LMNACYP3A4HPGDMAPT | |
| SCHEMBL957652 | 0.78 | CYP3A4 (0.40) | ALDH1A1CYP3A4CYP1A2HTR2A | |
| SCHEMBL7642548 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP3A4HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4194449-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-108017603-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2021-07-23 | — | — | CN | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5536745-A | (Hetero)-aryl ketones derivatives with antibacterial properties | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-07-16 | — | — | US | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | C9, CFB, C5 | ALDH1A1 3003/4885LMNA 1595/4885FFAR4 2318/4885 |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 3674/4885LMNA 4410/4885FFAR4 838/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 2779/4885LMNA 4320/4885FFAR4 1190/4885 |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | ALDH1A1 2066/4885LMNA 2845/4885FFAR4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.